In addition, in vitro experiments using simvastatin showed a significant reduction in IL-6 and IL-8 levels, suggesting that simvastatin may exert anti-inflammatory effects that could be relevant to CRC progression [24]. Here, IL6 is linked to colorectal carcinoma.